LENZ Therapeutics Inc (NASDAQ:LENZ) shares are trading higher by 2.6% to $28.72 during Monday’s session, though off their new 52-week high of $31.00, after the company announced the FDA accepted its new drug application for LNZ100 for the treatment of Presbyopia. What Else: LENZ says presbyopia is a vision condition affecting 1.8 billion people globally, including 128 million in the U.S. The FDA has set a target decision date of August 8, 2025, and will not hold an advisory committee meeting. LENZ CEO Eef Schimmelpennink expressed optimism about potential approval and the company’s efforts to …